Publicacións en colaboración con investigadores/as de Charles University in Prague (9)

2024

  1. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 53-59

  2. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching

    Rheumatology (United Kingdom), Vol. 63, Núm. 7, pp. 1882-1892

  3. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

    Arthritis and Rheumatology, Vol. 76, Núm. 4, pp. 587-598

2023

  1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  2. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    The Lancet Regional Health - Europe, Vol. 33

2022

  1. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

    Pharmacopsychiatry, Vol. 55, Núm. 2, pp. 73-86

  2. Erratum: Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels (Pharmacopsychiatry (2022) 55 2 (73-86))

    Pharmacopsychiatry

2020

  1. Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI

    Journal of the American College of Cardiology, Vol. 76, Núm. 20, pp. 2321-2330

2018

  1. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

    The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415